Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
Go back to Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®| Textainer Group Holdings limited (NASDAQ: GH) | Delayed: 128.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.83 | 52 Week High | $5.84 | |||
| Open | $128.83 | 52 Week Low | $5.49 | |||
| Day High | $128.83 | P/E | N/A | |||
| Day Low | $128.83 | EPS | $0.00 | |||
| Volume | 1,114 | |||||
